Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Amarin Corp Plc (AMRN)

Pharmaceutical Preparations

https://amarincorp.com

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.

SPACES SOUTH DOCKLANDS, BLOCK C, 77 SIR JOHN ROGERSON'S QUAY
DUBLIN 2, L2

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/01/1993

Market Cap

250,861,622

Shares Outstanding

387,900,000

Weighted SO

408,291,815

Total Employees

N/A

Upcoming Earnings

10/22/2009

Similar Tickers

SCLXW --.--%

BIIB --.--%

GILD --.--%

AZN --.--%

SNY --.--%

NVS --.--%

GSK --.--%

MRK --.--%

BMY --.--%

Beta

1.9600

Last Div

0.0000

Range

0.5701-1.37

Chg

-0.0086

Avg Vol

1760420

Mkt Cap

250861622

Exch

NASDAQ

Country

IE

Phone

353 1 669 9020

DCF Diff

0.8470

DCF

-0.2630

Div Yield

0.0000

P/S

0.9450

EV Multiple

-1.1882

P/FV

0.4543

Div Yield %

0.0000

P/E

-7.4689

PEG

-0.1765

Payout

0.0000

Current Ratio

3.0443

Quick Ratio

2.0058

Cash Ratio

0.9389

DSO

170.0637

DIO

742.4617

Op Cycle

912.5254

DPO

168.6547

CCC

743.8707

Gross Margin

0.5567

Op Margin

-0.1514

Pretax Margin

-0.1018

Net Margin

-0.1264

Eff Tax Rate

-0.2416

ROA

-0.0420

ROE

-0.0609

ROCE

-0.0706

NI/EBT

1.2416

EBT/EBIT

0.6725

EBIT/Rev

-0.1514

Debt Ratio

0.0101

D/E

0.0147

LT Debt/Cap

0.0145

Total Debt/Cap

0.0145

Int Coverage

36.8459

CF/Debt

-1.0714

Equity Multi

1.4493

Rec Turnover

2.1463

Pay Turnover

2.1642

Inv Turnover

0.4916

FA Turnover

34.9812

Asset Turnover

0.3319

OCF/Share

-0.0211

FCF/Share

-0.0224

Cash/Share

0.7477

OCF/Sales

-0.0327

FCF/OCF

1.0590

CF Coverage

-1.0714

ST Coverage

0.0000

CapEx Coverage

-16.9494

Div&CapEx Cov

-16.9494

P/BV

0.4543

P/B

0.4543

P/S

0.9450

P/E

-7.4689

P/FCF

-27.2992

P/OCF

-28.8914

P/CF

-28.8914

PEG

-0.1765

P/S

0.9450

EV Multiple

-1.1882

P/FV

0.4543

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 22, 07:30 Amarin Chairman & CEO Issue Letter to Shareholders The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today The Motley Fool Jan 10, 19:02 Why Amarin Stock Skyrocketed Today GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline GlobeNewswire Inc. Nov 12, 09:00 New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline The Motley Fool Nov 01, 12:30 Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript GlobeNewswire Inc. Oct 31, 12:00 Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

Revenue Product Segmentation